Core Points - The Hang Seng Index fell by 1.52% on October 13, closing at 25,889.48 points, while southbound funds through the Stock Connect recorded a net inflow of HKD 19.804 billion [1] - The total trading volume for the Stock Connect on October 13 was HKD 227.017 billion, with a net buy of HKD 19.804 billion [1] - Active stocks in the Shanghai Stock Connect included Alibaba-W, which had the highest trading volume at HKD 22.610 billion, followed by SMIC and Xiaomi Group with HKD 12.670 billion and HKD 9.133 billion respectively [1] - The top net buy stock was the Tracker Fund of Hong Kong, with a net inflow of HKD 5.208 billion, despite its closing price dropping by 1.56% [1] - Tencent Holdings had the highest net sell amount at HKD 3.308 billion, with a closing price decrease of 1.92% [1] Trading Activity Summary - In the Shenzhen Stock Connect, Alibaba-W led with a trading volume of HKD 9.688 billion, followed by Xiaomi Group and SMIC at HKD 6.189 billion and HKD 5.050 billion respectively [2] - The Tracker Fund of Hong Kong recorded a net buy of HKD 2.075 billion, while the highest net sell was for Innovent Biologics at HKD 0.515 billion, with a closing price drop of 4.20% [2] - The trading data for the top active stocks included significant fluctuations in net buy and sell amounts, indicating varied investor sentiment [2]

Group 1 - The Hang Seng Index fell by 1.52% on October 13, with a total southbound trading volume of HKD 227.017 billion, including HKD 123.411 billion in buying and HKD 103.606 billion in selling, resulting in a net buying amount of HKD 19.804 billion [1] - The southbound trading through Stock Connect (Shenzhen) had a total trading volume of HKD 78.738 billion, with net buying of HKD 12.206 billion, while the trading through Stock Connect (Shanghai) had a total volume of HKD 148.279 billion and net buying of HKD 7.598 billion [1] - Alibaba-W had the highest trading volume among southbound stocks, totaling HKD 32.298 billion, followed by SMIC and Xiaomi Group-W with HKD 17.721 billion and HKD 15.323 billion respectively [1] Group 2 - Among the active stocks, the top net buying stock was the Tracker Fund of Hong Kong with a net buying amount of HKD 7.282 billion, despite a closing price drop of 1.56% [2] - Xiaomi Group-W and ZTE Corporation had the longest consecutive net buying days, with 6 and 3 days respectively, and the highest net buying amounts of HKD 4.709 billion and HKD 1.673 billion [2] - The stocks with the highest net selling amounts included Tencent Holdings with HKD 2.445 billion, Alibaba-W with HKD 1.624 billion, and SMIC with HKD 0.524 billion [2]

Core Insights - On October 13, 2025, Alibaba-W (09988), SMIC (00981), and Xiaomi Group-W (01810) were the top three stocks by trading volume in the Southbound trading of the Stock Connect, with trading amounts of 22.61 billion, 12.67 billion, and 9.13 billion respectively [1] - In the Southbound trading of the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), Xiaomi Group-W (01810), and SMIC (00981) also ranked as the top three, with trading amounts of 9.69 billion, 6.19 billion, and 5.05 billion respectively [1] Shanghai-Hong Kong Stock Connect Top Active Companies - Alibaba-W (09988) had a trading amount of 22.61 billion with a net buy of -2.18 billion [1] - SMIC (00981) recorded a trading amount of 12.67 billion with a net buy of -1.81 billion [1] - Xiaomi Group-W (01810) had a trading amount of 9.13 billion with a net buy of +0.13 billion [1] - Tencent Holdings (00700) had a trading amount of 9.13 billion with a net buy of -3.31 billion [1] - The Yingfu Fund (02800) saw a trading amount of 5.42 billion with a net buy of +5.21 billion [1] - Hua Hong Semiconductor (01347) had a trading amount of 5.17 billion with a net buy of +0.79 billion [1] - Other notable companies included Hang Seng China Enterprises (02828), ZTE Corporation (00763), Meituan-W (03690), and Kingsoft Corporation (03888) with varying trading amounts and net buys [1] Shenzhen-Hong Kong Stock Connect Top Active Companies - Alibaba-W (09988) had a trading amount of 9.69 billion with a net buy of +0.55 billion [1] - Xiaomi Group-W (01810) recorded a trading amount of 6.19 billion with a net buy of +0.76 billion [1] - SMIC (00981) had a trading amount of 5.05 billion with a net buy of +1.29 billion [1] - Tencent Holdings (00700) had a trading amount of 4.47 billion with a net buy of +0.86 billion [1] - Hua Hong Semiconductor (01347) saw a trading amount of 3.04 billion with a net buy of +0.56 billion [1] - Other companies such as Yingfu Fund (02800), Meituan-W (03690), ZTE Corporation (00763), WuXi Biologics (02269), and Innovent Biologics (01801) also participated with varying trading amounts and net buys [1]

Core Insights - The Hong Kong stock market saw a net inflow of 198.04 billion HKD from northbound trading on October 13, with 75.98 billion HKD from the Shanghai Stock Connect and 122.06 billion HKD from the Shenzhen Stock Connect [1] Group 1: Stock Performance - The most bought stocks included the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and Hua Hong Semiconductor (01347) [1] - The most sold stocks were Tencent (00700), Alibaba-W (09988), and SMIC (00981) [1] - Alibaba-W had a buy amount of 102.16 billion HKD and a sell amount of 123.94 billion HKD, resulting in a net outflow of 21.78 billion HKD [2] - SMIC had a buy amount of 54.30 billion HKD and a sell amount of 72.40 billion HKD, leading to a net outflow of 18.10 billion HKD [2] - Tencent had a buy amount of 29.11 billion HKD and a sell amount of 62.19 billion HKD, resulting in a net outflow of 33.08 billion HKD [2] Group 2: Market Trends - The market is experiencing a decline in investor risk appetite due to escalating US-China trade tensions, which has led to a valuation correction in Hong Kong stocks [4] - Despite the current market challenges, there are expectations for stabilization in investor sentiment due to domestic growth-supporting policies and long-term measures to stabilize the stock market [4] - The semiconductor sector is showing divergence, with Hua Hong Semiconductor receiving a net inflow of 13.47 billion HKD, while SMIC faced a net outflow of 5.23 billion HKD [5] Group 3: Company-Specific News - Xiaomi Group-W (01810) saw a net inflow of 8.88 billion HKD despite a nearly 9% drop in its stock price due to safety concerns following a fire incident involving one of its vehicles [5] - Kingsoft (03888) received a net inflow of 2.86 billion HKD amid discussions on export controls related to rare earth materials [5] - Northbound trading sold off tech stocks, with Alibaba-W and Tencent facing significant net outflows of 24.45 billion HKD and 16.23 billion HKD, respectively [6]

Summary of WuXi Biologics Conference Call Company Overview - **Company**: WuXi Biologics - **Industry**: Pharmaceutical Services - **Market Position**: One of the top 5 largest biologics outsourcing service providers globally and the largest in China [43][62] Key Takeaways 1. Business Model and Efficiency - WuXi Biologics operates a strong royalty-based model, with approximately 90% of clients opting for cell-line royalties, ensuring recurring revenue linked to molecule success [3] - The company has achieved significant productivity improvements, with bispecific antibodies yielding 5-7 g/L and newer serine cell lines reaching 8-10 g/L, a five-fold increase compared to first-generation monoclonal antibodies [3][24][25] - These efficiency gains reduce scale requirements and enhance cost competitiveness, reinforcing WuXi's leadership in complex biologics manufacturing [3] 2. Global Expansion Strategy - WuXi is expanding its global footprint with two new U.S. sites near Princeton and Boston, targeting peak revenue of approximately $500 million within two years [4][21] - The cost of establishing U.S. facilities is about four times higher than in China, compounded by labor shortages and unpredictable tariff policies [4][22][23] - Singapore is identified as a strategic hub due to low tariffs and tax advantages, with over 100 Singaporeans currently being trained in China [4][27] 3. Geopolitical and Regulatory Landscape - Despite U.S.-China tensions, WuXi expects no direct impact from the Biosecure Act, as the company was not named in recent legislative drafts [5][35] - The company maintains a strong compliance and quality track record, having achieved FDA and EMA approvals without inspection [5] - WuXi is diversifying its capacity outside China to mitigate geopolitical risks while maintaining stable pricing with inflation-adjusted increases [5] 4. Financial Projections - Adjusted net profit projections for FY 2024A to FY 2027E are as follows: - 2024A: 4,784 million - 2025E: 5,078 million - 2026E: 6,101 million - 2027E: 7,148 million - Revenue projections for the same period are: - 2024A: 18,675.4 million - 2025E: 21,658.1 million - 2026E: 26,228.9 million - 2027E: 31,491.7 million [7] 5. Investment Recommendation - WuXi Biologics is rated as a "Buy" with a price target of HK$50.00, representing a potential upside of 19% from the current price of HK$42.18 [8] - The price target is based on a discounted cash flow (DCF) valuation methodology [44] 6. Risks and Opportunities - Risks include potential tariff increases and geopolitical tensions affecting operations [4][22] - Opportunities lie in the expected growth of core biologics segments, including monoclonal antibodies (mAbs), bispecifics, and emerging modalities like T-cell engagers (TCEs) and antibody-drug conjugates (ADCs) [5][40][41] 7. Sustainability and Corporate Governance - Key sustainability issues include corporate governance, business ethics, information security, and climate change [18][19] - The company aims to reduce greenhouse gas emissions intensity by 50% by 2030 and water consumption intensity by 18% by 2025 [19] 8. Market Dynamics - The U.S. market is facing challenges, but the FDA has relaxed certain requirements, which may benefit biosimilars in the long term [26] - Europe is expected to become increasingly important over the next decade due to population growth and rising demand [34] Conclusion WuXi Biologics is positioned for growth through its innovative business model, strategic global expansion, and strong compliance track record. However, it must navigate geopolitical risks and market dynamics to achieve its financial targets and maintain its leadership in the biologics outsourcing sector.

Core Insights - On October 10, 2025, Alibaba-W (09988), SMIC (00981), and Tencent Holdings (00700) were the top three companies by trading volume in the southbound trading of the Stock Connect, with trading amounts of 140.49 billion, 86.63 billion, and 42.68 billion respectively [1][2] - In the southbound trading of the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), SMIC (00981), and Tencent Holdings (00700) also ranked as the top three, with trading amounts of 77.88 billion, 48.07 billion, and 26.41 billion respectively [1][2] Southbound Trading Highlights - The top three active companies in the southbound trading of the Shanghai-Hong Kong Stock Connect were: - Alibaba-W (09988): 140.49 billion with a net buy of -13.44 billion - SMIC (00981): 86.63 billion with a net buy of -14.69 billion - Tencent Holdings (00700): 42.68 billion with a net buy of -11.60 billion [2] - The top three active companies in the southbound trading of the Shenzhen-Hong Kong Stock Connect were: - Alibaba-W (09988): 77.88 billion with a net buy of -4.67 billion - SMIC (00981): 48.07 billion with a net buy of -12.39 billion - Tencent Holdings (00700): 26.41 billion with a net buy of +2.09 billion [2]

Group 1 - Southbound funds recorded a net sell of HKD 399 million in Hong Kong stocks today [1] - Notable net purchases included Xiaomi Group-W at HKD 933 million, Pop Mart at HKD 669 million, and ZTE Corporation at HKD 490 million [1] - Significant net sells were observed in SMIC at HKD 2.709 billion, Alibaba-W at HKD 1.81 billion, and Tencent Holdings at HKD 951 million [1] Group 2 - Southbound funds have continuously net bought Xiaomi for 5 days, totaling HKD 3.82084 billion [1] - There has been a consecutive 2-day reduction in holdings for SMIC, amounting to HKD 5.105 billion [1] - A similar trend of reduction was noted for Hua Hong Semiconductor, with a total decrease of HKD 2.286 billion over 2 days [1]

Market Performance - The Hong Kong stock market continued its decline, with notable drops in several biotech companies [1] - Innovent Biologics (09969) fell by 11.19%, closing at 14.760, with a market capitalization of 26.021 billion and a year-to-date increase of 141.18% [2] - Rongchang Biologics (09995) decreased by 10.22%, with a latest price of 95.350 and a total market value of 53.74 billion, reflecting a year-to-date increase of 562.15% [2] - WuXi AppTec (02268) and WuXi Biologics (02269) experienced declines of 5.68% and 5.32%, respectively, with market caps of 89.818 billion and 1585.28 billion [2] - Other companies such as Fuhong Hanlin (02696) and Kelun-Biotech (06990) also saw declines of over 4% [1][2] Company Highlights - Innovent Biologics has shown a significant year-to-date performance increase of 141.18% despite the recent drop [2] - Rongchang Biologics has the highest year-to-date increase among the listed companies at 562.15% [2] - WuXi Biologics and WuXi AppTec have maintained strong year-to-date increases of 120.84% and 138.50%, respectively [2] - Fuhong Hanlin and Kelun-Biotech also reported substantial year-to-date increases of 205.49% and 199.33% [2]

Core Viewpoint - The Hong Kong biopharmaceutical stocks continued to decline, with significant drops in several key companies, indicating a bearish trend in the sector [1]. Group 1: Stock Performance - Innovent Biologics (09969) experienced a decline of 11.19%, with a latest price of 14.760 and a total market capitalization of 26.021 billion, despite a year-to-date increase of 141.18% [2]. - Rongchang Biologics (09995) fell by 10.22%, with a latest price of 95.350 and a market cap of 53.747 billion, showing a remarkable year-to-date increase of 562.15% [2]. - WuXi AppTec (02268) saw a decrease of 5.68%, with a latest price of 73.100 and a market cap of 89.818 billion, maintaining a year-to-date increase of 138.50% [2]. - WuXi Biologics (02269) dropped by 5.32%, with a latest price of 38.780 and a market cap of 158.528 billion, reflecting a year-to-date increase of 120.84% [2]. - Fuhong Hanlin (02696) declined by 4.42%, with a latest price of 72.400 and a market cap of 39.349 billion, showing a year-to-date increase of 205.49% [2]. - Kelun-Biotech (06990) decreased by 4.25%, with a latest price of 488.800 and a market cap of 113.981 billion, with a year-to-date increase of 199.33% [2]. - WuXi AppTec (02359) fell by 4.19%, with a latest price of 114.400 and a market cap of 339.275 billion, reflecting a year-to-date increase of 109.21% [2]. - Gendicine (09688) saw a decrease of 2.83%, with a latest price of 25.440 and a market cap of 28.432 billion, with a year-to-date increase of 21.72% [2]. - CanSino Biologics (09926) declined by 2.05%, with a latest price of 128.800 and a market cap of 118.643 billion, reflecting a year-to-date increase of 112.19% [2]. - Junshi Biosciences (01877) fell by 2.02%, with a latest price of 29.100 and a market cap of 29.877 billion, showing a year-to-date increase of 151.30% [2].

Summary of Conference Call Notes Industry Overview - The focus remains on the innovative drug sector, benefiting from business development (BD) transactions and data catalysts, with companies like Heng Rui continuing to push forward despite recent large transactions not meeting expectations [1][2] - The CRO (Contract Research Organization), CDMO (Contract Development and Manufacturing Organization), and upstream supply chain are benefiting from anticipated interest rate cuts in the U.S. and recovering order performance [1][2] - Medical devices, particularly high-consumption and equipment sectors, are showing signs of reversing performance difficulties, with Q3 expected to show improvement [1][2] Key Investment Strategies - Emphasis on the innovative drug line, with catalysts from the ESMO conference and BD transactions, alongside Q3 performance improvements [1][5] - Attention to the impact of basic drug directory policies and adjustments in traditional Chinese medicine companies, which may provide short-term catalysts [1][5] - Portfolio adjustments in October 2025 included increasing positions in companies like Changchun High-tech, Xianju Pharmaceutical, Betta Pharmaceuticals, and Tengke Pharmaceuticals, as well as companies showing performance inflection points [1][6] Core Recommendations - Recommended stocks based on three criteria: vertical extension capability in the supply chain, realization capability, and systematic early-stage R&D platform capability [9] - Specific recommendations include Changchun High-tech, Betta Pharmaceuticals, Amgen Pharmaceuticals, and Xiansheng Pharmaceuticals [9] - Notable mentions include Amgen, WuXi Biologics, and Miaomei Helian, expected to benefit from strong Taiji business, recovery in monoclonal antibody business, and high growth in ADC projects, with significant earnings growth anticipated in 2025 [1][19] Sector-Specific Insights - The innovative drug sector is viewed as the strongest and most fundamentally sound segment, with a focus on recovery from previous difficulties and policy changes [3][4] - CROs are showing early signs of recovery, with significant performance from WuXi and similar companies [3][4] - Medical devices are also recovering, with various companies performing well across different segments [4] Company-Specific Developments - **Betta Pharmaceuticals**: Notable for strong financial performance and ongoing business development, including an IPO process in Hong Kong expected to bring positive momentum [10] - **Amgen Pharmaceuticals**: Recently introduced strategic investment from Haizheng Pharmaceuticals, enhancing future growth prospects [11] - **Miaomei Helian**: Positioned as a leader in the ADC CRDMO sector, with significant growth expected from backend projects [20] - **Tianyu Co.**: Anticipated to maintain strong growth due to a diverse product pipeline and CDMO business expansion [25] - **Lianbang Pharmaceuticals**: Focused on innovative drugs, with several promising projects in clinical trials expected to drive future growth [26][27] Market Performance - The recommended portfolio showed an average increase of 5.5 percentage points in September, outperforming the broader pharmaceutical sector by 7.2 percentage points [6] - Specific stocks like Changchun High-tech and WuXi Biologics saw significant price increases of 26% and 23%, respectively [6] Conclusion - The innovative drug sector remains a key focus for investment, with several companies showing promising signs of recovery and growth potential. The overall sentiment is positive, with expectations for continued performance improvements in Q3 and beyond, driven by strategic investments and favorable market conditions [1][2][5]